Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

9 Oct 2015
Change (% chg)

$0.26 (+4.72%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for PGNX.OQ


Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in... (more)


Beta: 1.79
Market Cap(Mil.): $383.96
Shares Outstanding(Mil.): 69.68
Dividend: --
Yield (%): --


  PGNX.OQ Industry Sector
P/E (TTM): 99.64 52.14 33.98
EPS (TTM): 0.06 -- --
ROI: 2.16 -0.47 14.62
ROE: 2.80 -1.41 15.51
Search Stocks

Progenics Pharmaceuticals must pay $1.66 million for firing whistleblower - jury

- A federal jury ordered biotechnology company Progenics Pharmaceuticals Inc to pay $1.66 million, after finding that it retaliated against a former chemist in violation of whistleblower protections enacted after the Enron Corp scandal.

03 Aug 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks